Baiba K Gillard

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3605891/baiba-k-gillard-publications-by-year.pdf
Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

54 papers	1,293 citations	21 h-index	34 g-index
57 ext. papers	1,449 ext. citations	4.7 avg, IF	4.13 L-index

#	Paper	IF	Citations
54	High-density lipoproteins, reverse cholesterol transport and atherogenesis. *Nature Reviews Cardiology*, **2021**, 18, 712-723	14.8	15
53	Physico-chemical and physiological determinants of lipo-nanoparticle stability. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2021**, 33, 102361	6	0
52	High Free Cholesterol Bioavailability Drives the Tissue Pathologies in Scarb1 Mice. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, e453-e467	9.4	1
51	Dietary Alcohol and Fat Differentially Affect Plasma Cholesteryl Ester Transfer Activity and Triglycerides in Normo- and Hypertriglyceridemic Subjects. *Lipids*, **2020**, 55, 299-307	1.6	2
50	Highly conserved amino acid residues in apolipoprotein A1 discordantly induce high density lipoprotein assembly in vitro and in vivo. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2020**, 1865, 158794	5	2
49	Revisiting Reverse Cholesterol Transport in the Context of High-Density Lipoprotein Free Cholesterol Bioavailability. *Methodist DeBakey Cardiovascular Journal*, **2019**, 15, 47-54	2.1	10
48	Rethinking reverse cholesterol transport and dysfunctional high-density lipoproteins. *Journal of Clinical Lipidology*, **2018**, 12, 849-856	4.9	24
47	Somatic Editing of Ldlr With Adeno-Associated Viral-CRISPR Is an Efficient Tool for Atherosclerosis Research. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 1997-2006	9.4	41
46	Scavenger receptor B1 (SR-B1) profoundly excludes high density lipoprotein (HDL) apolipoprotein AII as it nibbles HDL-cholesteryl ester. *Journal of Biological Chemistry*, **2017**, 292, 8864-8873	5.4	22
45	Structural Stability of Streptococcal Serum Opacity Factor. *Protein Journal*, **2017**, 36, 196-201	3.9	
44	Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease. *Scientific Reports*, **2017**, 7, 44624	4.9	54
43	ABCA1-Derived Nascent High-Density Lipoprotein-Apolipoprotein AI and Lipids Metabolically Segregate. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 2260-2270	9.4	28
42	Direct Measurement of the Structure of Reconstituted High-Density Lipoproteins by Cryo-EM. *Biophysical Journal*, **2016**, 110, 810-6	2.9	14
41	Streptococcal serum opacity factor promotes cholesterol ester metabolism and bile acid secretion in vitro and in vivo. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2016**, 1861, 196-204	5	4
40	Native and Reconstituted Plasma Lipoproteins in Nanomedicine: Physicochemical Determinants of Nanoparticle Structure, Stability, and Metabolism. *Methodist DeBakey Cardiovascular Journal*, **2016**, 12, 146-150	2.1	12
39	Acylation of lysine residues in human plasma high density lipoprotein increases stability and plasma clearance in vivo. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2016**, 1861, 1787-1795	5	
38	Neo High-Density Lipoprotein Produced by the Streptococcal Serum Opacity Factor Activity against Human High-Density Lipoproteins Is Hepatically Removed via Dual Mechanisms. *Biochemistry*, **2016**, 55, 5845-5853	3.2	4

37	Apolipoprotein AI deficiency inhibits serum opacity factor activity against plasma high density lipoprotein via a stabilization mechanism. *Biochemistry*, **2015**, 54, 2295-302	3.2	4
36	High-Density Lipoprotein Therapies□hen and Now **2015**, 545-555		
35	High-Density Lipoprotein Processing and Premature Cardiovascular Disease. *Methodist DeBakey Cardiovascular Journal*, **2015**, 11, 181-5	2.1	4
34	Alcohol: a nutrient with multiple salutary effects. *Nutrients*, **2015**, 7, 1992-2000	6.7	6
33	Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. *Journal of Clinical Lipidology*, **2013**, 7, 661-70	4.9	16
32	Altered relationship of plasma triglycerides to HDL cholesterol in patients with HIV/HAART-associated dyslipidemia: further evidence for a unique form of metabolic syndrome in HIV patients. *Metabolism: Clinical and Experimental*, **2013**, 62, 1014-20	12.7	15
31	Free cholesterol determines reassembled high-density lipoprotein phospholipid phase structure and stability. *Biochemistry*, **2013**, 52, 4324-30	3.2	7
30	Setting the course for apoAII: a port in sight?. *Clinical Lipidology*, **2013**, 8, 551-560		8
29	Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 1714-21	9.4	21
28	Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients. *Medicine and Science in Sports and Exercise*, **2013**, 45, 1043-50	1.2	17
27	Cholesterol determines and limits rHDL formation from human plasma apolipoprotein A-II and phospholipid membranes. *Biochemistry*, **2012**, 51, 8627-35	3.2	7
26	Apolipoprotein E mediates enhanced plasma high-density lipoprotein cholesterol clearance by low-dose streptococcal serum opacity factor via hepatic low-density lipoprotein receptors in vivo. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 1834-41	9.4	21
25	Streptococcal serum opacity factor increases the rate of hepatocyte uptake of human plasma high-density lipoprotein cholesterol. *Biochemistry*, **2010**, 49, 9866-73	3.2	17
24	HDL superphospholipidation enhances key steps in reverse cholesterol transport. *Atherosclerosis*, **2010**, 209, 430-5	3.1	25
23	Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects. *Lipids*, **2010**, 45, 1117-26	1.6	9
22	Apolipoprotein modulation of streptococcal serum opacity factor activity against human plasma high-density lipoproteins. *Biochemistry*, **2009**, 48, 8070-6	3.2	18
21	Disruption of human plasma high-density lipoproteins by streptococcal serum opacity factor requires labile apolipoprotein A-I. *Biochemistry*, **2009**, 48, 1481-7	3.2	22
20	Apolipoproteins A-I, A-II and E are independently distributed among intracellular and newly secreted HDL of human hepatoma cells. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2009**, 1791, 1125-32	5	32

19	Properties of the products formed by the activity of serum opacity factor against human plasma high-density lipoproteins. *Chemistry and Physics of Lipids*, **2008**, 156, 45-51	3.7	5
18	Serum opacity factor unmasks human plasma high-density lipoprotein instability via selective delipidation and apolipoprotein A-I desorption. *Biochemistry*, **2007**, 46, 12968-78	3.2	38
17	Speciation of human plasma high-density lipoprotein (HDL): HDL stability and apolipoprotein A-I partitioning. *Biochemistry*, **2007**, 46, 7449-59	3.2	41
16	Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2). *Journal of Lipid Research*, **2007**, 48, 348-57	6.3	50
15	N-Glycosylation is required for secretion-competent human plasma phospholipid transfer protein. *Protein Journal*, **2006**, 25, 167-73	3.9	5
14	Plasma factors required for human apolipoprotein A-II dimerization. *Biochemistry*, **2005**, 44, 471-9	3.2	12
13	Decreased synthesis of glycosphingolipids in cells lacking vimentin intermediate filaments. *Experimental Cell Research*, **1998**, 242, 561-72	4.2	52
12	Pathways of glycosphingolipid biosynthesis in SW13 cells in the presence and absence of vimentin intermediate filaments. *Glycobiology*, **1996**, 6, 33-42	5.8	31
11	Variable subcellular localization of glycosphingolipids. *Glycobiology*, **1993**, 3, 57-67	5.8	76
10	Biosynthesis of the blood group Pk and P1 antigens by human kidney microsomes. *Carbohydrate Research*, **1992**, 228, 277-87	2.9	13
9	Association of glycosphingolipids with intermediate filaments of mesenchymal, epithelial, glial, and muscle cells. *Cytoskeleton*, **1992**, 21, 255-71		56
8	Association of glycosphingolipids with intermediate filaments of human umbilical vein endothelial cells. *Experimental Cell Research*, **1991**, 192, 433-44	4.2	62
7	Interferon-gamma alters expression of endothelial cell-surface glycosphingolipids. *Archives of Biochemistry and Biophysics*, **1990**, 279, 122-9	4.1	32
6	Measurement and significance of antibodies against GM1 ganglioside. Report of a workshop, 18 April 1989, Chicago, IL, U.S.A. *Journal of Neuroimmunology*, **1989**, 25, 255-9	3.5	76
5	Isolation and purification of gangliosides from plasma. *Methods in Enzymology*, **1987**, 138, 300-6	1.7	31
4	Glycosphingolipids of human umbilical vein endothelial cells and smooth muscle cells. *Archives of Biochemistry and Biophysics*, **1987**, 256, 435-45	4.1	53
3	A solvent partition method for microscale ganglioside purification. *Analytical Biochemistry*, **1985**, 146, 220-31	3.1	160
2	Cystic fibrosis serum pancreatic amylase. Useful discriminator of exocrine function. *American Journal of Diseases of Children*, **1984**, 138, 577-80		10

1	Serum amylase isoenzymes in cystic fibrosis patients. Evidence for a generalized defect in exocrine gland secretory regulation. *Pediatric Research*, **1980**, 14, 1168-72	3.2	8